

Dear Friends,

Please find below the 51st NEWSLETTER of the International Extranodal Lymphoma Study Group.

IELSG further expands collaboration

The collaboration envisaged at the beginning of April 2016, during the meeting “*Avances en linfoma: Linfomas extranodales y linfomas T*” in Santiago (Chile) by the participants on lymphoma research and management is about to be realized.

A draft protocol on Retrospective Study on T-Cell Neoplasms (a Clinico Pathological Characteristic of Primary Gastrointestinal T and NK Cell Lymphomas in Latin America) has been discussed among several Latin American investigators and the IELSG representative during a concomitant meeting at the International Conference on Malignant Lymphoma last June in Lugano. The enthusiasm of the Steering Committee can make us foresee the launch of this study by the end of this year.

Current status of the IELSG trials

The total accrual of prospective, retrospective and biological IELSG trials has almost reached 7'000 patients.

Ongoing prospective clinical studies

IELSG30 – A phase II study of R-CHOP with intensive CNS prophylaxis and scrotal irradiation in patients with primary testicular diffuse large B-cell lymphoma

The study, now open only in Italy for insurance reasons, has recruited 53 of the expected 54. Only 1 patient is now missing to complete the accrual and we kindly ask you a last effort.

IELSG37 – A randomized, open-label, multicenter, two-arm phase III comparative study assessing the role of involved mediastinal radiotherapy after Rituximab containing chemotherapy regimens to patients with newly diagnosed Primary Mediastinal Large B-Cell Lymphoma (PMLBCL)

A total of 359 and 299 PET have been reviewed: 150 were positive and 149 negative. From these 149 were PET negative; 75 of them have been randomized in Arm A (Radiotherapy) and 74 in Arm B (Observation Only). The remaining 150 were positive.

IELSG40 – A phase II Trial addressing feasibility and activity of Clarithromycin plus Lenalidomide combination: A full oral treatment for patients with relapsed/refractory mucosa-associated lymphoid tissue lymphoma (CLEO)

The CLEO trial is a phase II trial for the treatment of MALT lymphoma with Clarithromycin and Lenalidomide. Patients with gastric or extragastric disease are eligible at first or greater relapse after prior radiotherapy, chemotherapy or immunotherapy. Sixty-two is the planned number of evaluable patients to recruit. At present, a total of 7 patients have been enrolled, 3 in Italy and 4 in Austria. After the Summer, additional Italian sites will be included in the trial and more centers are expected to open in Spain later this year.

IELSG42 – An international phase II trial assessing tolerability and efficacy of sequential Methotrexate-Aracytin-based combination and R-ICE combination, followed by high-dose chemotherapy supported by

autologous stem cell transplant, in patients with systemic B-cell lymphoma with central nervous system involvement at diagnosis or relapse (MARIETTA regimen)

Aim of the IELSG 42 study is to evaluate the efficacy and feasibility of a new sequential combination of HD-MTX-AraC-based chemoimmunotherapy, followed by R-ICE regimen, and by high-dose chemotherapy supported by ASCT. The study is open in Italy, UK, The Netherland and Czech Republic. So far 46 of the planned 76 patients have already been enrolled. Other active centers are expected soon in France, Israel and Switzerland.

IELSG43 – High-dose chemotherapy and autologous stem cell transplant or consolidating conventional chemotherapy in primary CNS lymphoma - randomized phase III trial (MATRix)

The aim of this randomized phase III trial is to optimize the treatment of patients with PCNSL less than 70 years old by comparing HDT and ASCT to an optimized non- stem-cell supported consolidating therapy.

This is the first randomized trial in PCNSL which will probably give an answer to the question whether high-dose-chemotherapy within the first-line treatment is superior to conventional therapy as consolidation after intensified immunochemotherapy in newly diagnosed PCNSL at the highest level of evidence.

So far, 145 patients have been enrolled: 141 in Germany and 4 in Italy, where several centers have already been activated. Other active centers are available in Norway and Denmark. This study will also be activated in Switzerland and Czech Republic. The end of trial (250 patients to enroll) is expected by first quarter 2018.

New prospective trials

IELSG45 – Randomized Phase II Trial on Fitness- and Comorbidity- Tailored Treatment in Elderly Patients with Newly Diagnosed Primary CNS Lymphoma (FIORELLA Trial)

This is a multicenter open label phase II trial for patients aged 70 years or more, with newly diagnosed PCNSL. We expect to enroll 208 patients in total, who will be stratified according to their suitability to tolerate an induction chemoimmunotherapy regimen containing high-dose methotrexate.

The study will be submitted to Ethics Committees and Health Authorities by 2017.

Ongoing retrospective studies

IELSG 17 – Multi-institutional retrospective analysis of intravascular lymphomatosis

Sixty-eight patients have been enrolled in 15 countries: 33 in Italy, 7 in Spain, 4 in Australia, 3 in France Greece, Hungary, Israel and in the Netherlands, 2 Argentina and Switzerland, 1 in Belgium, Germany, Poland, Sweden and US.

Mark your presence @

IELSG Meeting 2018

March 16-17, 2018 Stresa (Italy)

Register now on www.ieslg.org